In the US warned about the risk of losing sight due to popular injections for weight loss

The U.S. Food and Drug Administration (FDA) has reported a potentially increased risk of non-arteritis anterior ischemic optical neuropathy. This severe optic nerve disease can occur in people using GLP-1 RA weight loss drugs.

According to the regulator, this condition can provoke sudden loss of vision. The FDA has posted information on its website.

In this regard, manufacturers of products containing semaglutide and liraglutide should add a risk warning to the packaging. The regulator made such a request to pharmaceutical companies.

Patients who use injections to lose weight are advised to closely monitor their condition. If there is a deterioration in vision, its clouding or distortion of color perception, you should immediately consult a doctor.

A study presented at the Congress of the European Academy of Dermatology and Venereology in 2026, for the first time associated taking GLP-1 drugs with nail and hair problems: nail detachment was recorded in 39% of those taking such products against 9% in the control group, and unusual hair loss was reported by 50% versus 34%. The authors emphasize that when these symptoms appear, you should not stop treatment yourself - they should be discussed with a doctor.